Rui Kong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rui Kong has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Bei Sun
Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
12 shared publications - Gang Wang
The First Affiliated Hospital of Harbin Medical University
12 shared publications - Le Li
Department of Pancreatic and Biliary Surgery The First Affiliated Hospital of Harbin Medical University Harbin China
12 shared publications - Hua Chen
Department of Pancreatic and Biliary Surgery, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
11 shared publications - Jisheng Hu
The First Affiliated Hospital of Harbin Medical University 1 Department of Pancreatic and Biliary Surgery Harbin, China
11 shared publications - Can Zhang
The First Affiliated Hospital of Harbin Medical University 1 Department of Pancreatic and Biliary Surgery Harbin, China
10 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 1 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary figure 1. The prognostic implication of DM for pancreatic cancer. a. Forest plot showing the association between DM and the incidence of PDAC. b. Logistics analysis of potential predictors of development of PDAC.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 1 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary figure 1. The prognostic implication of DM for pancreatic cancer. a. Forest plot showing the association between DM and the incidence of PDAC. b. Logistics analysis of potential predictors of development of PDAC.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Patients with pancreatic ductal adenocarcinoma (PDAC) with diabetes mellitus (DM) exhibit poor clinical outcomes. Metabolic reprogramming of both cancer cells and immune compartments plays a crucial role in shaping the antitumor immune response in PDAC. DM-induced metabolic alteration may disrupt the intricate cross-talk between immune cells and tumor-associated immune factors, profoundly influencing PDAC progression. In this study, we performed an integrated, spatially resolved multiomics study to investigate DM-associated, cell-specific metabolic remodeling within the PDAC tumor microenvironment. DM influenced interactions between tumor cells and immune cells, which accelerated PDAC growth in both humans and mice. Patients with PDAC with DM exhibited higher tumor stage, poorer differentiation, and worse outcomes. Spatial metabolic and transcriptional profiling revealed that SREBP2-dependent cholesterol biosynthesis exacerbated PDAC progression. Increased cholesterol biosynthesis promoted neutrophil recruitment and accelerated the formation of neutrophil extracellular traps (NET) by stimulating the CXCL1/CXCR1/CXCR2 signaling axis, ultimately promoting PDAC growth. Inhibition of SREBP2, pharmacologic blockade of CXCL1, or perturbation of NETs markedly reduced PDAC growth in diabetic mouse models. Together, these multiomics analyses and follow-up mechanistic studies constitute an integrated approach that elucidates a metabolic mechanism by which diabetes promotes PDAC development by remodeling the tumor-immune microenvironment and highlights a potential therapeutic strategy for PDAC with DM.Significance:Diabetes induces metabolic reprogramming that promotes neutrophil recruitment and neutrophil extracellular trap formation to drive pancreatic cancer progression, providing a targetable metabolism-immune axis to improve the outcomes of diabetic pancreatic cancer patients.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Patients with pancreatic ductal adenocarcinoma (PDAC) with diabetes mellitus (DM) exhibit poor clinical outcomes. Metabolic reprogramming of both cancer cells and immune compartments plays a crucial role in shaping the antitumor immune response in PDAC. DM-induced metabolic alteration may disrupt the intricate cross-talk between immune cells and tumor-associated immune factors, profoundly influencing PDAC progression. In this study, we performed an integrated, spatially resolved multiomics study to investigate DM-associated, cell-specific metabolic remodeling within the PDAC tumor microenvironment. DM influenced interactions between tumor cells and immune cells, which accelerated PDAC growth in both humans and mice. Patients with PDAC with DM exhibited higher tumor stage, poorer differentiation, and worse outcomes. Spatial metabolic and transcriptional profiling revealed that SREBP2-dependent cholesterol biosynthesis exacerbated PDAC progression. Increased cholesterol biosynthesis promoted neutrophil recruitment and accelerated the formation of neutrophil extracellular traps (NET) by stimulating the CXCL1/CXCR1/CXCR2 signaling axis, ultimately promoting PDAC growth. Inhibition of SREBP2, pharmacologic blockade of CXCL1, or perturbation of NETs markedly reduced PDAC growth in diabetic mouse models. Together, these multiomics analyses and follow-up mechanistic studies constitute an integrated approach that elucidates a metabolic mechanism by which diabetes promotes PDAC development by remodeling the tumor-immune microenvironment and highlights a potential therapeutic strategy for PDAC with DM.Significance:Diabetes induces metabolic reprogramming that promotes neutrophil recruitment and neutrophil extracellular trap formation to drive pancreatic cancer progression, providing a targetable metabolism-immune axis to improve the outcomes of diabetic pancreatic cancer patients.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 3 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary figure 3. The cluster analysis for spatial transcriptomics. a. Mapping of cell clusters to spatial locations in all samples. b. UMAP visualizing 15 clusters in all samples. Comparison of 15 spatial clusters between two groups using UMAP. c. Heatmap plotting markers for all clusters.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 3 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary figure 3. The cluster analysis for spatial transcriptomics. a. Mapping of cell clusters to spatial locations in all samples. b. UMAP visualizing 15 clusters in all samples. Comparison of 15 spatial clusters between two groups using UMAP. c. Heatmap plotting markers for all clusters.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 6 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary figure 6. DM promotes PDAC progression through SREBP2-induced NETs formation. a. Western blot assay compared the protein level of SREBP2 between control and Betulin-treated tumor cells. The mRNA level of SREBP2 between control and Betulin-treated tumor cells. Comparison of cholesterol level in the supernatant of tumor cells between control and Betulin-treated tumor cells. b. The mRNA level of CXCL1 in the Pan02 cells following the inhibition of SREBP2 or cholesterol biosynthesis and the level of CXCL1 in the cellular supernatant (n = 3). c. The expression of CXCL1 in the tumors of control, betulin and simvastatin groups (Scale bar = 100 µm, n = 6). d. Levels of cholesterol within tumor tissues in different treatment conditions. e. WT and Pad4-/- mice were injected with STZ to induce diabetes. Mice were then injected with Pan02 cells and sacrificed 3 weeks after tumor implantation. Representative images (duplicates) of pancreatic orthotopic tumors. Scale bar represents 5 mm. The tumor volume and weight at the endpoint were compared. f. Representative immunofluorescence images and quantification of CD45+ Ly6g + cells in the tumors (Scale bar = 100 µm, n = 5). Green, CD45 positive cell; Red, Ly6g positive cell. g. Confirmation of SREBP2 knockdown in Pan02 cells determined by western blotting. h. Representative images of western blot and quantification of total and phosphorylation of NF-κB and AKT proteins in the pancreatic cells (SW 1990) stimulated by Betulin. i. The serum cholesterol between shNC and shSREBP2 groups. j. The levels of CXCL1 in the cellular supernatant of shNC and shSREBP2 groups (n = 5). The level of cholesterol in the shNC and shSREBP2 PAN02 cells (n = 3). k. The relative mRNA expression of CXCL1 and the cellular supernatant level of CXCL1 in Pan02 (shNC and shSREBP2) cells stimulated by NF-κB inhibitor (DHMEQ). l. The relative mRNA expression of CXCL1 and the cellular supernatant level of CXCL1 in Pan02 (shNC and shSREBP2) cells stimulated by AKT inhibitor (PI3K/AKT-IN-1).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 6 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary figure 6. DM promotes PDAC progression through SREBP2-induced NETs formation. a. Western blot assay compared the protein level of SREBP2 between control and Betulin-treated tumor cells. The mRNA level of SREBP2 between control and Betulin-treated tumor cells. Comparison of cholesterol level in the supernatant of tumor cells between control and Betulin-treated tumor cells. b. The mRNA level of CXCL1 in the Pan02 cells following the inhibition of SREBP2 or cholesterol biosynthesis and the level of CXCL1 in the cellular supernatant (n = 3). c. The expression of CXCL1 in the tumors of control, betulin and simvastatin groups (Scale bar = 100 µm, n = 6). d. Levels of cholesterol within tumor tissues in different treatment conditions. e. WT and Pad4-/- mice were injected with STZ to induce diabetes. Mice were then injected with Pan02 cells and sacrificed 3 weeks after tumor implantation. Representative images (duplicates) of pancreatic orthotopic tumors. Scale bar represents 5 mm. The tumor volume and weight at the endpoint were compared. f. Representative immunofluorescence images and quantification of CD45+ Ly6g + cells in the tumors (Scale bar = 100 µm, n = 5). Green, CD45 positive cell; Red, Ly6g positive cell. g. Confirmation of SREBP2 knockdown in Pan02 cells determined by western blotting. h. Representative images of western blot and quantification of total and phosphorylation of NF-κB and AKT proteins in the pancreatic cells (SW 1990) stimulated by Betulin. i. The serum cholesterol between shNC and shSREBP2 groups. j. The levels of CXCL1 in the cellular supernatant of shNC and shSREBP2 groups (n = 5). The level of cholesterol in the shNC and shSREBP2 PAN02 cells (n = 3). k. The relative mRNA expression of CXCL1 and the cellular supernatant level of CXCL1 in Pan02 (shNC and shSREBP2) cells stimulated by NF-κB inhibitor (DHMEQ). l. The relative mRNA expression of CXCL1 and the cellular supernatant level of CXCL1 in Pan02 (shNC and shSREBP2) cells stimulated by AKT inhibitor (PI3K/AKT-IN-1).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 2 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary figure 2. Spatially resolved multi-omics reveals intratumor heterogeneity in PDAC. a. Graphic scheme of human cohorts used in this study. Strategy of integrated spatially resolved multi-omics for indicating PDAC metabolic remodeling and interactions under DM. b. Metabolites in the tumor area. c. OPLS-DA analysis indicating the clustering of all samples. d. MSEA analysis showing enriched metabolic pathways based on differential expressed metabolites in tumor-region.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 2 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary figure 2. Spatially resolved multi-omics reveals intratumor heterogeneity in PDAC. a. Graphic scheme of human cohorts used in this study. Strategy of integrated spatially resolved multi-omics for indicating PDAC metabolic remodeling and interactions under DM. b. Metabolites in the tumor area. c. OPLS-DA analysis indicating the clustering of all samples. d. MSEA analysis showing enriched metabolic pathways based on differential expressed metabolites in tumor-region.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary Table 1. Characteristics of primary PDAC samples (HTAN) with diabetes status.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary Table 1. Characteristics of primary PDAC samples (HTAN) with diabetes status.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 5 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary figure 5. DM promotes colorectal and breast cancer progression in mice models. a. Representative images and quantification of Ki-67 positive cells in tumor tissues by IHC (Scale bar = 50 µm, n = 6). b. Comparison of N2 polarized neutrophils between tumors obtained from DM and control groups using mIHC, scale bar = 50 μm. c. Experimental outline of murine subcutaneous colorectal cancer model. d. Representative images of tumor size. Scale bar represents 5 mm. The tumor volume and weight were compared. e. Growth curves of subcutaneous tumors. f. Representative immunofluorescence images and quantification of CD45+ Ly6g+ and MPO + CitH3+ cells in MC38 tumors (Scale bar = 100 µm, n = 5). Green, CD45 and CitH3 positive cell; Red, Ly6g and Mpo positive cell. g. Experimental outline of murine subcutaneous breast model. h. Representative images of subcutaneous breast tumors. Scale bar represents 5 mm. i. The tumor volumes and weight were compared. j. Representative immunofluorescence images and quantification of MPO + CitH3+ cells in the breast tumors (Scale bar = 100 µm, n = 5). k. Representative images of oil red staining in the SW1990 cells stimulated by high concentration of glucose (HG) versus normal glucose (NG). The levels of cholesterol in cellular supernatant were detected (n = 3). L. Flow cytometry gating strategy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 5 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary figure 5. DM promotes colorectal and breast cancer progression in mice models. a. Representative images and quantification of Ki-67 positive cells in tumor tissues by IHC (Scale bar = 50 µm, n = 6). b. Comparison of N2 polarized neutrophils between tumors obtained from DM and control groups using mIHC, scale bar = 50 μm. c. Experimental outline of murine subcutaneous colorectal cancer model. d. Representative images of tumor size. Scale bar represents 5 mm. The tumor volume and weight were compared. e. Growth curves of subcutaneous tumors. f. Representative immunofluorescence images and quantification of CD45+ Ly6g+ and MPO + CitH3+ cells in MC38 tumors (Scale bar = 100 µm, n = 5). Green, CD45 and CitH3 positive cell; Red, Ly6g and Mpo positive cell. g. Experimental outline of murine subcutaneous breast model. h. Representative images of subcutaneous breast tumors. Scale bar represents 5 mm. i. The tumor volumes and weight were compared. j. Representative immunofluorescence images and quantification of MPO + CitH3+ cells in the breast tumors (Scale bar = 100 µm, n = 5). k. Representative images of oil red staining in the SW1990 cells stimulated by high concentration of glucose (HG) versus normal glucose (NG). The levels of cholesterol in cellular supernatant were detected (n = 3). L. Flow cytometry gating strategy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 7 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary figure 7. Single cell sequencing revealed that DM promotes PDAC progression by increasing neutrophil infiltration. a. Schematic diagram showed the experimental design of multi-omics in diabetic PDAC progression. b. Heatmap plotting markers for all clusters. c. Pathway analysis from KEGG analysis showing metabolism-related pathways enriched by different genes in cancer cells between DM and Non-DM groups. d. The expression of CXCL1 in cancer cells. e. Functional enrichment of up-regulated genes in the cancer cells between DM and Non-DM groups. f. KEGG analysis showing the pathways enriched by up-regulated genes in neutrophils between DM and Non-DM groups.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 7 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary figure 7. Single cell sequencing revealed that DM promotes PDAC progression by increasing neutrophil infiltration. a. Schematic diagram showed the experimental design of multi-omics in diabetic PDAC progression. b. Heatmap plotting markers for all clusters. c. Pathway analysis from KEGG analysis showing metabolism-related pathways enriched by different genes in cancer cells between DM and Non-DM groups. d. The expression of CXCL1 in cancer cells. e. Functional enrichment of up-regulated genes in the cancer cells between DM and Non-DM groups. f. KEGG analysis showing the pathways enriched by up-regulated genes in neutrophils between DM and Non-DM groups.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 4 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary figure 4. Spatial transcriptomics deciphers the immune landscape underlying diabetic pancreatic cancer. a. The relative mRNA expression of CXCL8, CXCL6, CCL20, CCL13 and CXCL9 in the tumor region between DM and Non-DM groups. b. The spatial expressions of C3 and HIST1H4J which are associated with neutrophil extracellular traps formation pathway at spatial level. c. The number of MPO + CitH3+ cells in field were calculated between DM and Non-DM groups (PDAC, n = 5, PDAC with DM, n = 5). d. Bar chart showing the percentage of 22 immune subgroups in PDAC. e. Bar chart showing cell proportions of 22 immune subgroups between PDAC and PDAC with DM groups. f. Spatial resolved gene expression images and expression level of N2-meutrophils between DM and non-DM groups.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 4 from Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Supplementary figure 4. Spatial transcriptomics deciphers the immune landscape underlying diabetic pancreatic cancer. a. The relative mRNA expression of CXCL8, CXCL6, CCL20, CCL13 and CXCL9 in the tumor region between DM and Non-DM groups. b. The spatial expressions of C3 and HIST1H4J which are associated with neutrophil extracellular traps formation pathway at spatial level. c. The number of MPO + CitH3+ cells in field were calculated between DM and Non-DM groups (PDAC, n = 5, PDAC with DM, n = 5). d. Bar chart showing the percentage of 22 immune subgroups in PDAC. e. Bar chart showing cell proportions of 22 immune subgroups between PDAC and PDAC with DM groups. f. Spatial resolved gene expression images and expression level of N2-meutrophils between DM and non-DM groups.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (10) , 2327-2343
Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Patients with pancreatic ductal adenocarcinoma (PDAC) with diabetes mellitus (DM) exhibit poor clinical outcomes. Metabolic reprogramming of both cancer cells and immune compartments plays a crucial role in shaping the antitumor immune response in PDAC. DM-induced metabolic alteration may disrupt the intricate cross-talk between immune cells and tumor-associated immune factors, profoundly influencing PDAC progression. In this study, we performed an integrated, spatially resolved multiomics study to investigate DM-associated, cell-specific metabolic remodeling within the PDAC tumor microenvironment. DM influenced interactions between tumor cells and immune cells, which accelerated PDAC growth in both humans and mice. Patients with PDAC with DM exhibited higher tumor stage, poorer differentiation, and worse outcomes. Spatial metabolic and transcriptional profiling revealed that SREBP2-dependent cholesterol biosynthesis exacerbated PDAC progression. Increased cholesterol biosynthesis promoted neutrophil recruitment and accelerated the formation of neutrophil extracellular traps (NET) by stimulating the CXCL1/CXCR1/CXCR2 signaling axis, ultimately promoting PDAC growth. Inhibition of SREBP2, pharmacologic blockade of CXCL1, or perturbation of NETs markedly reduced PDAC growth in diabetic mouse models. Together, these multiomics analyses and follow-up mechanistic studies constitute an integrated approach that elucidates a metabolic mechanism by which diabetes promotes PDAC development by remodeling the tumor-immune microenvironment and highlights a potential therapeutic strategy for PDAC with DM. Significance: Diabetes induces metabolic reprogramming that promotes neutrophil recruitment and neutrophil extracellular trap formation to drive pancreatic cancer progression, providing a targetable metabolism-immune axis to improve the outcomes of diabetic pancreatic cancer patients.
- 9 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (10) , 2327-2343
Open AccessSpatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Patients with pancreatic ductal adenocarcinoma (PDAC) with diabetes mellitus (DM) exhibit poor clinical outcomes. Metabolic reprogramming of both cancer cells and immune compartments plays a crucial role in shaping the antitumor immune response in PDAC. DM-induced metabolic alteration may disrupt the intricate cross-talk between immune cells and tumor-associated immune factors, profoundly influencing PDAC progression. In this study, we performed an integrated, spatially resolved multiomics study to investigate DM-associated, cell-specific metabolic remodeling within the PDAC tumor microenvironment. DM influenced interactions between tumor cells and immune cells, which accelerated PDAC growth in both humans and mice. Patients with PDAC with DM exhibited higher tumor stage, poorer differentiation, and worse outcomes. Spatial metabolic and transcriptional profiling revealed that SREBP2-dependent cholesterol biosynthesis exacerbated PDAC progression. Increased cholesterol biosynthesis promoted neutrophil recruitment and accelerated the formation of neutrophil extracellular traps (NET) by stimulating the CXCL1/CXCR1/CXCR2 signaling axis, ultimately promoting PDAC growth. Inhibition of SREBP2, pharmacologic blockade of CXCL1, or perturbation of NETs markedly reduced PDAC growth in diabetic mouse models. Together, these multiomics analyses and follow-up mechanistic studies constitute an integrated approach that elucidates a metabolic mechanism by which diabetes promotes PDAC development by remodeling the tumor-immune microenvironment and highlights a potential therapeutic strategy for PDAC with DM. Significance: Diabetes induces metabolic reprogramming that promotes neutrophil recruitment and neutrophil extracellular trap formation to drive pancreatic cancer progression, providing a targetable metabolism-immune axis to improve the outcomes of diabetic pancreatic cancer patients.